Brief: Sangamo Therapeutics To Regain Full Rights To Hemophilia A Gene Therapy Program Following Pfizer’S Decision To Cease Development Of Giroctocogene Fitelparvovec

Sangamo Therapeutics

30/12/2024 21:26

Dec 30 (Reuters) - Sangamo Therapeutics Inc  SGMO.O :
    * SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A
GENE
THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT
OF GIROCTOCOGENE FITELPARVOVEC
    * SANGAMO THERAPEUTICS: INTENDS TO EXPLORE OPTIONS TO
ADVANCE
PROGRAM, INCLUDING SEEKING POTENTIAL NEW COLLABORATION PARTNER
    * SANGAMO THERAPEUTICS INC: COLLABORATION AND LICENSE
AGREEMENT
WITH PFIZER WILL TERMINATE EFFECTIVE APRIL 21, 2025
    * SANGAMO THERAPEUTICS INC: ALL TRIAL PARTICIPANTS WILL
CONTINUE
TO BE MONITORED AS PLANNED DURING TRANSITION PERIOD

Source text:  ID:nBw35RTKxa 
Further company coverage:  SGMO.O 

 ((Reuters.Briefs@thomsonreuters.com;))